NCT02540538View on ClinicalTrials.gov

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Hepatitis B
Interventions
BIOLOGICAL

HBVaxPro

3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.

BIOLOGICAL

HBAI20

2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.

Trial Locations (1)

6202 AZ

Maastricht UMC, Maastricht

Sponsors

Collaborators (1)

CyTuVax
All Listed Sponsors
collaborator

CyTuVax

OTHER

lead

Maastricht University Medical Center

OTHER